tradmap

AIM AIM ImmunoTech Inc.

$0.24 +5.84%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

AIM ImmunoTech Inc. (AIM) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $7 million. Shares last traded at $0.24, 92.9% below their 52-week high. Over the past year the stock is down 90.1%. Revenue declined 48.2% year over year.

Market Cap
$7M
Shares Out
30.4M
EPS (TTM)
$-18.71
P/E Ratio
P/S Ratio
76.31
P/B Ratio
0.94
Dividend / Share
Dividend Yield
52-Week High
$3.37
52-Week Low
$0.20
Volume
180,380
Avg Vol (3m)
78,681.619

Performance

1W
-5.80%
1M
-13.31%
3M
-56.90%
6M
-62.81%
YTD
-80.15%
1Y
-90.08%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. AIM split history →

Technicals

RSI (14)
45.39
SMA (50)
$0.26
SMA (200)
$0.72
Price vs SMA50
-9.05%
Price vs SMA200
-66.99%
ATR (14)
$0.03

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$0M
Net Income
$-14M
Gross Margin
Operating Margin
Net Margin
Return on Equity
-184.3%
Return on Assets
-112.1%
Current Ratio
2.11
Debt / Equity
0.47
Revenue Growth (YoY)
-48.2%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.96 2026-08-07
Q1 2026 $-0.69 2026-05-15
FY 2025 $-8.62 2026-03-27
Q3 2025 $-8.18 2025-11-17
Q2 2026 $-8.88 2026-08-07
Q1 2026 $-0.05 2026-05-15

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

AIM vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
76.31 / 19.49 med
+291% premium
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.